Status:

COMPLETED

Oral LAT8881 in Neuropathic Pain

Lead Sponsor:

Lateral Pharma Pty Ltd

Conditions:

Neuropathic Pain

Diabetic Peripheral Neuropathy (DPN)

Eligibility:

All Genders

18-75 years

Phase:

PHASE2

Brief Summary

This is a randomised, placebo-controlled, double-blind, crossover, phase IIa study to investigate the efficacy and safety of oral LAT8881 in neuropathic pain.

Detailed Description

This is a randomised, placebo-controlled, double-blind, crossover, phase IIa study to investigate the efficacy and safety of oral LAT8881 in neuropathic pain. After a one week baseline period, subject...

Eligibility Criteria

Inclusion

  • Clinical diagnosis of post herpetic neuralgia, with pain persisting for at least 3 months after the onset of herpes zoster rash OR
  • Clinical diagnosis of distal painful polyneuropathy due to Type I or Type II diabetes mellitus with:
  • symmetrical, bilateral pain in the lower extremities for at least 3 months and
  • diabetes under control for at least 3 months prior to randomisation, as indicated by a glycated haemoglobin level (HbA1c) of ≤ 11% (97 mmol/mol) and on a stable dose of insulin or oral diabetic medication for 3 months prior to screening, and
  • no change in diabetic medication planned for the duration of the study
  • Positive sensory symptoms (mechanical or thermal) associated with neuropathic pain, confirmed by:
  • painDETECT questionnaire (PD-Q) and
  • Clinical assessment, showing signs of neuropathic pain in either a dermatomal (PHN) or distal symmetrical distribution (DPN)
  • 8\. An average daily pain score on the numeric pain rating scale (NPRS) of at least 4 and no more than 8 in the last five diary entries before randomisation

Exclusion

  • Presence of moderate to severe pain from other causes that may confound assessment or self-evaluation of NP.
  • Subjects with both DPN and PHN

Key Trial Info

Start Date :

April 9 2019

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

May 3 2020

Estimated Enrollment :

53 Patients enrolled

Trial Details

Trial ID

NCT03865953

Start Date

April 9 2019

End Date

May 3 2020

Last Update

June 14 2021

Active Locations (6)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 2 (6 locations)

1

Paratus Clinical Research Kanwal

Kanwal, New South Wales, Australia, 2259

2

Paratus Clinical Research Blacktown

Sydney, New South Wales, Australia, 2148

3

AusTrials

Brisbane, Queensland, Australia, 4075

4

Emeritus Research Services

Melbourne, Victoria, Australia, 3124